Passage Bio

Passage Bio is a clinical-stage genetic medicines company dedicated to improving the lives of patients suffering from neurodegenerative diseases. Their primary focus is on developing cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Their lead product candidate, PBFT02, aims to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels, which helps restore lysosomal function and slows disease progression. Passage Bio is committed to collaborating with scientists, physicians, patients, and health authorities worldwide to conduct thorough clinical trials and ultimately deliver safe and effective treatments.

Passage Bio's approach utilizes adeno-associated viruses (AAVs) to deliver functional therapeutic genes to patients. They are currently exploring the therapeutic potential of elevating progranulin levels in the central nervous system to alter the course of neurodegenerative diseases. Passage Bio is dedicated to addressing the underlying pathology of genetically-driven neurodegenerative diseases and is committed to working with patient advocacy groups to provide support and educational resources to empower patients and caregivers.

Passage Bio offers a comprehensive benefits package for all employees, including a focus on work-life balance. This includes paid maternity/paternity leave and opportunities for flexible work arrangements, though specific details about the types of flexibility offered (like remote work or flexible hours) are not explicitly mentioned in the job posting.

Passage Bio offers a comprehensive benefits package that includes competitive salaries, an all-employee bonus program, long-term incentives with a discounted stock purchase plan, a benefits package covering domestic partners, 401K with company match, paid maternity/paternity leave, and a collaborative and fun work environment.

Passage Bio is a clinical-stage genetic medicines company dedicated to improving the lives of patients with neurodegenerative diseases. They focus on developing cutting-edge, one-time therapies designed to target the underlying pathology of these conditions, with a particular emphasis on elevating progranulin levels to restore lysosomal function and slow disease progression. Their mission is to permanently redefine the course of neurodegenerative diseases and protect patients and their families from the devastating effects of these conditions.

Passage Bio fosters a culture that prioritizes innovation, collaboration, and patient-centricity. They emphasize a commitment to excellence in research and development, with a focus on delivering life-transforming therapies for neurodegenerative diseases. Their core values include putting patients at the center of every decision, applying leading-edge science, and acting with integrity. The company promotes a fun and collaborative work environment with opportunities for growth and development, recognizing that their team members are key to achieving their mission.

Passage Bio embraces diversity, equity, and inclusion (DEI) as fundamental to the success of the company and the communities it serves. Their commitment to DEI is evident in their community programs, hiring practices, and internal events, where they promote and foster a welcoming environment that celebrates the diverse backgrounds and perspectives of their workforce.